All In Biotech

Drug Trial Radar · NCT07112339

A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes

EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 586 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

586

Planned (sponsor's estimate)

Start

Aug 15, 2025

Primary completion

Mar 23, 2028

Study completion Mar 23, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • Insulin icodecDrug

    Insulin icodec will be administered as subcutaneous injection.

  • Basal insulin analoguesDrug

    Basal insulin analogues will be administered as subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in glycated haemoglobin (HbA1c)Time frame: From baseline week 0 to week 52

Locations

75 sites in 3 countries. Site status is shown where the registry gives one.

  • Recherche Clinique Sigma Inc.

    Québec, Canada · Recruiting

  • Diex Recherche Quebec

    Québec, Canada · Recruiting

  • Centre de Recherche Saint-Louis

    Québec, Canada · Recruiting

  • Alpha Recherche Clinique - Lebourgneuf

    Québec, Canada · Recruiting

  • Centricity Research Calgary Endocrinology

    Calgary, Alberta, Canada · Recruiting

  • Alta Clinical Research at Hermitage Medicentre

    Edmonton, Alberta, Canada · Recruiting

  • Fraser Clinical Trials Inc.

    New Westminster, British Columbia, Canada · Recruiting

  • Winnipeg Clinic

    Winnipeg, Manitoba, Canada · Recruiting

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, Canada · Recruiting

  • Centricity Research Brampton Endocrinology

    Brampton, Ontario, Canada · Recruiting

  • Centricity Clinical Research Burlington

    Burlington, Ontario, Canada · Completed

  • Centricity Research Vaughn Endocrinology

    Concord, Ontario, Canada · Recruiting

  • Medical Trust Clinics, Inc.

    Courtice, Ontario, Canada · Completed

  • Centricity Research Etobicoke Endocrinology

    Etobicoke, Ontario, Canada · Recruiting

  • Janik Research

    Greater Sudbury, Ontario, Canada · Recruiting

  • Hamilton Medical Research Group

    Hamilton, Ontario, Canada · Recruiting

  • St. Josephs Health Care

    London, Ontario, Canada · Recruiting

  • Western Univ. Cnt for Studies in Fam Med

    London, Ontario, Canada · Recruiting

  • Malton Medical Clinic

    Mississauga, Ontario, Canada · Completed

  • Centricity Research Ottawa LMC

    Nepean, Ontario, Canada · Recruiting

  • The Ottawa Hospital_Riverside

    Ottawa, Ontario, Canada · Not yet recruiting

  • Bluewater Clin Res Group Inc

    Sarnia, Ontario, Canada · Completed

  • Sewa Ram Singal Medicine Professional Corp

    Toronto, Ontario, Canada · Recruiting

  • Centricity Research Toronto

    Toronto, Ontario, Canada · Recruiting

  • Centricity Research Toronto Manna Multispec

    Toronto, Ontario, Canada · Completed

  • Diex Recherche Joliette

    Joliette, Quebec, Canada · Recruiting

  • Alpha Recherche Clinique - Clinique de Levis

    Lévis, Quebec, Canada · Recruiting

  • Centricity Research Mirabel

    Mirabel, Quebec, Canada · Recruiting

  • Centre hospitalier de l'Universite de Montreal

    Montreal, Quebec, Canada · Not yet recruiting

  • McGill University Health Centre

    Montreal, Quebec, Canada · Not yet recruiting

  • Applied Medical Informatics Research

    Montreal, Quebec, Canada · Recruiting

  • Clinique Endocrinologie OASIS.

    Montreal, Quebec, Canada · Recruiting

  • Centricity Res Pointe-Claire

    Pointe-Claire, Quebec, Canada · Recruiting

  • ALPHA Recherche Clinique

    Québec, Quebec, Canada · Completed

  • Diex Recherche Sherbrooke

    Sherbrooke, Quebec, Canada · Completed

  • Centre de Recherche Saint-Louis

    Sherbrooke, Quebec, Canada · Recruiting

  • Ctr de Med Metab de Lanaudiere

    Terrebonne, Quebec, Canada · Recruiting

  • Diex Recherche Trois-Rivieres

    Trois-Rivières, Quebec, Canada · Recruiting

  • Diex Recherche Victoriaville

    Victoriaville, Quebec, Canada · Recruiting

  • Diabetespraxis Mergentheim

    Bad Mergentheim, Germany · Recruiting

Showing 40 of 75 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.